George Mason University Antonin Scalia Law School

Will Increasing the Term of Data Exclusivity for Biologic Drugs in the TPP Reduce Access to Medicines?

The following guest post comes from Philip Stevens, Director of the Geneva Network, a research and advocacy organization working on international health, trade, and intellectual property issues. The original research note can be found here.

By Philip Stevens

scientist looking through a microscopeIn the Trans-Pacific Partnership (TPP) negotiations, the U.S. Read more